Obesity at MS diagnosis linked to higher current and subsequent levels of disability

Written By :  Dr. Kamal Kant Kohli
Published On 2022-12-06 04:30 GMT   |   Update On 2022-12-06 07:03 GMT
Advertisement

Researchers have found in a new study that Obesity at multiple sclerosis diagnosis linked to higher current and subsequent levels of disability. Further carrying far too much weight when diagnosed with multiple sclerosis is tied to disability within a relatively short period of time.

The research has been published online in the Journal of Neurology Neurosurgery & Psychiatry.

Reverting to a healthy weight may improve clinical outcomes for obese patients with MS, suggest the researchers.

Obesity during childhood and adolescence is associated with a heightened risk of developing MS, irrespective of other potential environmental triggers. But it's not clear if it might also be linked to faster disability progression after diagnosis.

To try and find out, the researchers drew on 1066 participants with relapsing-remitting MS from across Germany who were taking part in The German National MS (NationMS) study. More than a quarter (29.5%, 315) of them were men with an average age of 33.

When MS was diagnosed, 159 patients (15%) were obese with a BMI of at least 30. Co-existing conditions associated with obesity (type 2 diabetes, high blood pressure) were reported in 68 patients (just under 6.5%).

Their levels of disability were monitored every 2 years for a total of 6 years, using the Expanded Disability Status Scale (EDSS). This ranges from 0 to 10 in 0.5 unit increments. Obesity at diagnosis wasn't associated with a higher annual relapse rate, or greater build-up of nerve damage, as seen on MRI brain scans, over the 6-year monitoring period.

But levels of disability were higher at the time of diagnosis and at each of the subsequent three time points, after factoring in age, sex, and smoking. And the average time it took obese patients to accumulate greater levels of disability was shorter. They reached EDSS 3 at just under 12 months, on average, compared with nearly 18 months for those who weren't obese.

Obese patients were also more than twice as likely to reach EDSS 3 within 6 years, irrespective of what type of drug treatment they were getting. Complete health data were available for 81 (51%) of the obese MS patients and for 430 (just under 47.5%) of the others.

The risk of reaching EDSS 3 within 6 years in this group was again more than twice as high in obese patients as it was in those who weren't, falling to an 84% heightened risk after factoring in sex, age, and smoking.

Importantly, overweight (BMI 25–29.9) at diagnosis wasn't significantly associated with higher disability then or subsequently, or with a heightened risk of reaching an EDSS of 3 after 6 years.

This is an observational study, and as such, can't establish cause. And the researchers acknowledge that BMI was assessed only once at the start of the study while co-existing conditions were limited to type 2 diabetes and high blood pressure, with the number of those affected, small.

But previous research has linked a reduction in brain grey matter with obesity, they point out.

"Our finding that obesity, but not overweight in MS patients, is associated with a poorer outcome suggests a threshold effect of body mass on disability accumulation in MS," they write, adding that obesity is a modifiable risk factor.

"These data suggest that dedicated management of obesity should be explored for its potential merit in improving long-term clinical outcomes of patients diagnosed with MS," they conclude.

Reference:

Lutfullin I, Eveslage M, Bittner S, et alAssociation of obesity with disease outcome in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry Published Online First: 01 November 2022. doi: 10.1136/jnnp-2022-329685

Tags:    
Article Source : Journal of Neurology Neurosurgery & Psychiatry

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News